Neuroprotective strategies in alzheimer's disease

Advances in Experimental Medicine and Biology

Volumn 513, Issue , 2002, Pages 475-496

  Behl, Christian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,6 TRIMETHYLPHENOL; ACETYLSALICYLIC ACID; ALPHA 2 MACROGLOBULIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN E4; BETA SECRETASE; CORTICOTROPIN RELEASING FACTOR; CYCLOOXYGENASE 2 INHIBITOR; ENZYME INHIBITOR; ESTRADIOL; ESTROGEN; GINKGO BILOBA EXTRACT; IBUPROFEN; IDEBENONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NAPROXEN; NEUROTROPHIC FACTOR; NEUROTROPHIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRESENILIN 1; PRESENILIN 2; PROSTAGLANDIN SYNTHASE INHIBITOR; SECRETASE INHIBITOR; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN METABOLISM; CLINICAL TRIAL; DEMENTIA; DRUG TARGETING; FAMILIAL DISEASE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE MAPPING; GENE MUTATION; GENE TARGETING; GENETICS; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; MOLECULAR CLONING; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEUROTOXICOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; RISK FACTOR; SIDE EFFECT; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MEMBRANE PROTEINS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PRESENILIN-1; RISK FACTORS; SENILE PLAQUES;

GINKGO BILOBA;

EID: 0036935502     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (88)

1. Alzheimer A. ber eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschr Psychiat Psych-Gericht Med 1907; 64:146-148.
2. Masters CL, Beyreuther K. Alzheimer s disease. BMJ 1998; 316: 446-448.
3. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer s disease. Nature 399: A23-A31.
4. Haass C, Mandelkow E. Proteolysis by presenilins and the renaissance of tau. Trends Cell Biol 1999; 9:241-244.
5. Whitehouse PJ, Price DL, Struble RG et al. Alzheimer s disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982; 215:1237-1239.
6. Cacabelos R, Alvarez A, Lombardi A et al. Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000; 36:415-499.
7. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD et al. Complement activation by β-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992; 89:10016-10020.
8. McGeer EG, McGeer PL. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharmac Design 1999; 5: 821-836.
9. Breitner JCS. The role of antiinflammatory drugs in the prevention and treatment of Alzheimer s disease. Annu Rev Med 1996; 47:401-411.
10. Eikelenboom P, Rozemuller AJM, Hoozemans JJM et al. Neuroinflammation and Alzheimer disease: Clinical and therapeutic implications. Alz Dis Ass Dis 2000; 14(Suppl 1):S54-S61.
11. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: An update. Exp Gerontol 2000; 35(9-10 SI):1363-1372.
12. Beal MF. Aging, energy, and oxidative stress in neurodegenerative disorders. Ann Neurol 1995; 38:357-366.
13. Behl C. Alzheimer s disease and oxidative stress: Implications for novel therapeutic approaches. Prog Neurobiol 1999; 57:301-323.
14. Harman D. Aging: Phenomena and theories. Ann NY Acad Sci 1998; 854:1-7.
15. Markesbery WR. The role of oxidative stress in Alzheimer disease. Arch Neurol 1999; 56:1449-1452.
16. Behl C, Davies J, Cole GM et al. Vitamin E protects nerve cells from amyloid b protein toxicity. Biochem Bioph Res Co 1992; 186:944-950.
17. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997; 77(4):1081-1132.
18. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer s disease. N Engl J Med 1997; 336:1216-1222.
19. Selkoe DJ. Alzheimers disease: Genes, proteins, and therapy. Physiol Rev 2001; 81(2):741-766.
20. Yankner BA. Mechanisms of neuronal degeneration in Alzheimers disease. Neuron 1996; 16:921-932.
21. Behl C. Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tiss Res 1997; 290:471-480.
22. Mandelkow E, Mandelkow EM. Microtubules and microtubule-associated proteins. Curr Opin Cell Biol 1995; 7(1):72-81.
23. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases Trends Neurosci 1998; 21(10):428-433.
24. Chen M, Fernandez HL. Where do Alzheimer s plaques and tangles come from? Aging-induced protein degradation inefficiency. Front Biosci 2001; 6:E1-E11.
25. Chapman PF, Falinska AM, Knevett SG et al. Genes, models and Alzheimer s disease. Trends Genet 2001; 17(5):254-261.
26. Campion D, Dumanchin C, Hannequin D et al. Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999; 65(3):664-670.
27. Schubert D, Behl C. The expression of amyloid beta protein precursor protects nerve cells from beta-amyloid and glutamate toxicity and alters their interaction with the extracellular matrix. Brain Res 1993; 629:275-282.
28. Mattson MP, Cheng B, Culwell AR et al. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993; 10:243-254.
29. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20(4):154-159.
30. Wolfe MS, Haass C. The role of presenilins in gamma-secretase activity. J Biol Chem 2001; 276(8):5413-5416.
31. Skovronsky DM, Lee VMY. Beta-secretase revealed: Starting gate for race to novel therapies for Alzheimer s disease. Trends Pharmacol Sci 2000; 21(5):161-163.
32. Lammich S, Kojro E, Postina R et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 1999; 96(7):3922-3927.
33. Xu H, Gouras GK, Greenfield JP et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998; 4:447-451.
34. Manthey D, Heck S, Engert S et al. Estrogen induces a rapid secretion of amyloid β precursor protein via the mitogen-activated protein kinase pathway. Eur J Biochem 2001; 268:1-8.
35. Yah SD, Chen X, Fu J et al. Rage and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382(6593):685-691.
36. Liu Y, Dargusch R, Schubert D. Beta amyloid toxicity does not require rage protein. Biochem Biophys Res Co 1997; 237(1):37-40.
37. Behl C, Davies JB, Lesley R et al. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994; 77:817-827.
38. Geula C, Wu CK, Saroff D et al. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nature Med 1998; 4(7):827-831.
39. Behl C, Lezoualch F, Trapp T et a. Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinol 1997; 138(1):101-106.
40. Behl C. Apoptosis and Alzheimer s disease. J Neur Transm 2000; 107:1325-1344.
41. Terry RD. The pathogenesis of alzheimer disease An alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1996; 55(10):1023-1025.
42. Terry RD, Katzman R, Bick KL. Alzheimer Disease. New York: Raven Press, 1994.
43. Rebeck GW, Reiter JS, Strickland DK et al. Apolipoprotein E in sporadic Alzheimer s disease: Allelic variation and receptor interactions. Neuron 1993; 11(4):575-580.
44. Richard F, Amouyel P. Genetic susceptibility factors for Alzheimer s disease. Eur J Pharmacol 2001; 412(1):1-12.
45. Simons M, Keller P, Destrooper B et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95(11):6460-6464.
46. Wolozin B, Kellman W, Rousseau P et al. Decreased prevalence of Alzheimer disease associated with 3-hYdroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57(10):1439-1443.
47. Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer s disease beta-amyloid peptides A beta 42 and A beta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98(10):5856-5861.
48. Kojro E, Gimpl G, Lammich S et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 2001; 98(10):5815-5820.
49. Emilien G, Maloteaux JM, Beyreuther K et al. Alzheimer disease Mouse models pave the way for therapeutic opportunities. Arch Neurol 2000; 57(2):176-181.
50. Duff K, Knight H, Refolo LM et al. Characterization of pathology in transgenic mice overexpressing human genomic and cDNA tau transgenes. Neurobiol Dis 2000; 7(2):87-98.
51. Emilien G, Beyreuther K, Masters CL et al. Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol 2000; 57(4):454-459.
52. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999; 400(6740):173-177.
53. Janus C, Pearson J, McLaurin J et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer s disease. Nature 2000; 408(6815):979-982.
54. Morgan D, Diamond DM, Gottschall PE et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer s disease. Nature 2000; 408(6815):982-985.
55. Lim GP, Yang F, Chu T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer s disease. J Neurosci 2000; 20(15):5709-5714.
56. Grundman M. Vitamin E and Alzheimer disease: The basis for additional clinical trials. Am J Clin Nutr 2000; 71(2):630S-636S.
57. Moosmann B, Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci USA 1999; 96:8867-8872.
58. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer s disease: update on a 2-year double-blind multicentre study. J Neur Transm 1998; (Suppl 54):301-310.
59. Guidetti C, Paracchini S, Lucchini S et al. Prevention of neuronal cell damage induced by oxidative stress in-vitro: Effect of different Ginkgo biloba extracts. J Pharm Pharmacol 2001; 53(3):387-392.
60. Oken BS, Storzbach DM, Kaye JA. The efficacy of ginkgo biloba on cognitive function in Alzheimer-disease. Arch Neurol 1998; 55(11):1409-1415.
61. Wesnes KA, Ward T, McGinty A et al. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacol 2000; 152(4):353-361.
62. Nourhashemi F, Gillette-Guyonnet S, Andrieu S et al. Alzheimer disease: Protective factors. Am J Clin Nutr 2000; 71(2):643S-649S.
63. Games D, Adams D, Alessandrini R et al. Alzheimer-type neuropathology in transgenic mice overexpressing v717f beta-amyloid precursor protein. Nature 1995: 373(6514):523-527.
64. Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer s disease. Neurobiol Aging 1994; 15(Suppl 2):S195-S197.
65. Henderson VW, Paganini-Hill A, Emanuel CK et al. Estrogen replacement therapy in older women. Arch Neurol 1994; 51:896-900.
66. Tang MX, Jacobs D, Stern Y et al Effect of oestrogen during menopause on risk and age of onset of Alzheimer s disease. Lancet 1996; 348:429-432.
67. Henderson VW. Oestrogens and dementia. In: Novartis Found Symp, ed. 2000; 230:254-265.
68. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999; 20:279-307.
69. Behl C, Widmann M, Trapp T et al. 17-β estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Com 1995; 216:473-482.
70. Green PS, Bishop J, Simpkins JW. 17 alpha-estradiol exerts neuroprotective effects on SK-N-SH cells. J Neurosci 1997; 17:511-515.
71. Behl C, Holsboer F. The female sex hormone oestrogen as a neuroprotectant. Trends Pharmacol Sci 1999; 20(11):441-444.
72. Behl C. Estrogen Mystery drug for the brain? The neuroprotective activities of the female sex hormone. Wien, NewYork: Springer, 2001.
73. Green PS, Simpkins JW. Neuroprotective effects of estrogens: Potential mechanisms of action. Intern J Develop Neurosci 2000; 18:347-358.
74. Petanceska SS, Nagy V, Frail D, Gandy S. Ovariectomy and 17 beta-estradiol modulate the levels of Alzheimer s amyloid beta peptides in brain. Neurology 2000; 54:2212-2217.
75. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrine Rev 1996; 17:187-205
76. Lezoualc h F, Engert S, Berning B et al. Corticotropin-releasing hormone mediated neuroprotection against oxidative stress is associated with the increased release of non amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappa B. Mol Endocrinol 2000; 14(1):147-159.
77. Behan DP, Grigoriadis DE, Lovenberg T et al. Neurobiology of corticotropin releasing factor (CRH) receptors and CRH-binding protein: Implications for the treatment of CNS disorders. Mol Psych 1996; 1:265-277.
78. Lezoualch F, Sagara Y, Holsboer F et al. High constitutive nf-kappa-b activity mediates resistance to oxidative stress in neuronal cells. J Neurosci 1998; 18(9):3224-3232
79. Greeve I, Hermans-Borgmeyer I, Brellinger C et al. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer s disease-associated neurodegeneration and oxidative stress. J Neurosci 2000; 20(19):7345-7352.
80. Borchelt DR, Ratovitski T, Vanlare J et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997; 19(4):939-945.
81. Destrooper B, Saftig P, Craessaerts K et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391(6665):387-390.
82. Duff K, Eckman C, Zehr C et al. Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383(6602):710-713.
83. Holcomb L, Gordon MN, Mcgowan E et al. Accelerated alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med 1998; 4(1):97-100.
84. Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, a-beta elevation, and amyloid plaques in transgenic mice. Science 1996; 274(5284):99-102.
85. Sturchler-Pierrat C, Abramowski D, Duke M et al. Two amyloid precursor protein transgenic mouse models with alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997; 4(24):13287-13292.
86. Zheng H, Jiang MH, Trumbauer ME et al. Beta-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995; 81(4):525-31.
87. Shen J, Bronson RT, Chen DF, Xia WM, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in presenilin-1-deficient mice. Cell 1997; 89(4):629-639.
88. McGeer PL, McGeer EG, Yasojima K. Alzheimer disease and neuroinflammation. J Neural Transm Suppl 2000; 59:53-57.